Find answers to common questions about being compliant with USP <800> and how it will impact your compounding pharmacy practice.

+-What is the Purpose of USP <800>?

General Chapter <800> Hazardous Drugs–Handling in Healthcare Settings was formally published February 1, 2016 in the First Supplement to USP 39-NF 34. USP <800> is established in concert with USP General Chapters <795> for non-sterile compounding and <797> for sterile compounding. The purpose of the chapter is to provide standards and define processes to protect personnel, patients, and the environment when handling hazardous drugs (HDs) in a healthcare setting. Building on existing standards and guidelines, General Chapter <800> provides a comprehensive approach for handling hazardous drugs with the ultimate goal of preventing and/or minimizing exposure to hazardous drugs.

 
+-Does USP <800> apply to non-sterile compounding practices?

Yes – USP <800> is established in concert with USP General Chapters <795> for non-sterile compounding and <797> for sterile compounding.

 
+-Who needs to comply with USP <800>?

The chapter applies to healthcare personnel and entities that handle hazardous drugs; this list includes pharmacists, pharmacy technicians, nurses, physicians, physician assistants, home healthcare workers, veterinarians, and veterinary technicians.

 
+-How does USP <800> define a hazardous drug?

The chapter does not list specific hazardous drugs, but refers to the most current National Institute for Occupational Safety and Health (NIOSH) list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. Drugs identified on this list are considered hazardous or potentially hazardous with respect to at least one of the following six criteria: carcinogenicity, teratogenicity or developmental toxicity, reproductive toxicity in humans, organ toxicity at low doses in humans or animals, genotoxicity, and new drugs that mimic existing hazardous drugs in structure or toxicity. To view for a full list of hazardous drugs please visit https://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf.

 
+-When does USP <800> come into effect?

In an effort to provide an adequate timeframe to implement USP <800> standards, the chapter has a delayed official implementation date of July 1, 2018. While a nearly two-year window may seem to provide sufficient time for preparation, it is important to note that the implementation date of July 1, 2018 is when entities must be compliant with USP <800>; waiting too long to begin the process could negatively impact your practice.

 
+-What health effects has workplace exposure been shown to be associated with?

When not properly protected through the use of personal protective equipment and engineering controls, occupational exposure has been shown to be associated with health effects such as skin rashes, decreased fertility, spontaneous abortions, congenital malformations, and possibly leukemia and other cancers.

 
+-What additional training does my staff require for USP <800> compliance?

Even if the right controls (e.g., personal protective equipment, engineering controls) are in place, occupational exposure can occur if these controls are not being used properly or if personnel are inappropriately handling hazardous drugs. Personnel training and verification of competency is imperative to risk minimization in the workplace, making it one of the most important aspects of a hazardous drug exposure control program. Pharmacy personnel must be educated and trained in all aspects of working with hazardous substances. Any personnel expected to handle or come in contact with a hazardous substance, either directly or indirectly, should complete a thorough training program on working with hazardous drugs as well as risk mitigation techniques.

Facilities that handle hazardous drugs must have a hazardous communication program in place. As such, each employee who may be exposed to hazardous chemicals when working shall be provided with information regarding the occupational risks associated with the facility-specific hazardous drugs and training on proper handling procedures, prior to their initial assignment to work with a hazardous chemical.

 
+-Do I need separate equipment to compound hazardous drugs?

Segregation is an important aspect of exposure control and there must be designated equipment for hazardous drug compounding as this will minimize the likelihood of cross-contamination. Hazardous compounding equipment that requires segregation from non-hazardous compounding equipment may include balances, mortars, pestles, spatulas, stir bars, beakers, cylinders, and counting trays. Pharmacies must also perform a risk assessment to determine whether specific technologies can be used with hazardous drugs. For example, hazardous drugs in the form of capsules and tablets must not be placed in an automated counting machine or packaging machine as these devices put stress on the dosage form, potentially resulting in the release of powder into the work environment.

 
+-Which type of room do I need to compound hazardous drug preparations?

Containment-Primary Engineering Controls (C-PECs) for both sterile and non-sterile compounding must be housed within a room segregated from non-hazardous compounding rooms. This room is called the Containment-Secondary Engineering Control (C-SEC) and must maintain negative pressure with respect to the adjacent rooms, such that if contamination were to occur, it would be contained within the room by the inflow of air down a gradient of between 0.01-0.03 inches of water column. The C-SEC must also maintain the minimum Air Changes Per Hour (ACPH) as described by USP <800>. Furthermore, the room must be externally exhausted to the outside of the building. For sterile compounding, the C-SEC must also maintain compliance with the required ISO quality air as described in USP <797>.

 
+-What are the venting requirements for containment primary engineering controls?

According to USP <800>, C-PECs used for non-sterile hazardous drug compounding must be externally vented through HEPA filtration (preferred) or internally vented through at least two HEPA filters in series. For sterile hazardous drug compounding, the C-PEC must be externally vented through HEPA filtration.

 
+-Do I still need to use a containment primary engineering control if I use a closed-system transfer device (CSTD) to compound all hazardous drug preparations?

CSTDs are a supplemental engineering control that should be used as an adjunct to primary and secondary engineering controls. The use of CSTDs has been shown to effectively reduce surface contamination and worker exposure, but does not totally eliminate the risk.

 
+-Do I need a special kind of glove to handle hazardous drugs?

Yes, gloves worn for hazardous compounding are required to meet the American Society for Testing and Materials (ASTM) standard D6978 (or its successor). Double gloving is required when working with hazardous substances.

 

Need help preparing for USP <800>? Check out our offerings below!

 

Live Trainings

Essential Elements of Hazardous Drug Compounding

Essential Elements of Hazardous Drug Compounding

 
 

Current Regulations and Standards for Pharmacy Compounding – How to be Compliant

Current Regulations and Standards for Pharmacy Compounding – How to be Compliant

 
 

Essential Elements of Compounded Sterile Preparations

Essential Elements of Compounded Sterile Preparations

 
 

Webinars

Sterile Cleanroom Design: Hazardous Drug Compounding

Sterile Cleanroom Design: Hazardous Drug Compounding

 
 

Implementing USP <800>: Personal Protective Equipment Requirements

Implementing USP <800>: Personal Protective Equipment Requirements